Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001214659-25-015518·Lakefront Biotherapeutics NV
Schedule 13G ownership disclosure
LAKEFRONT BIOTHERAPEUTICS NV
Ordinary shares, no par value · CUSIP: 36315X101
Event date: 2025-10-27
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TANG CAPITAL MANAGEMENT, LLC
Shares: 5,559,674.00 · Class: 8.4%
- KEVIN TANG
Shares: 5,559,674.00 · Class: 8.4%
- TANG CAPITAL PARTNERS, LP
Shares: 3,313,189.00 · Class: 5.0%
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
Shares: 2,246,485.00 · Class: 3.4%
- TANG CAPITAL PARTNERS III, INC
Shares: 0.00 · Class: 0.0%
- TANG CAPITAL PARTNERS IV, INC
Shares: 0.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-25-015518
- Form type
- SCHEDULE 13G
- Filer
- Lakefront Biotherapeutics NV
- CIK
- CIK 1421876
- Filed
- Oct 29, 2025
- Reporting period
- Oct 27, 2025
- Description
- Schedule 13G beneficial ownership